IL299381A - Methods of treating neuromyelitis optica spectrum disorder - Google Patents

Methods of treating neuromyelitis optica spectrum disorder

Info

Publication number
IL299381A
IL299381A IL299381A IL29938122A IL299381A IL 299381 A IL299381 A IL 299381A IL 299381 A IL299381 A IL 299381A IL 29938122 A IL29938122 A IL 29938122A IL 299381 A IL299381 A IL 299381A
Authority
IL
Israel
Prior art keywords
subject
need
spectrum disorder
neuromyelitis optica
treatment
Prior art date
Application number
IL299381A
Other languages
English (en)
Hebrew (he)
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of IL299381A publication Critical patent/IL299381A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL299381A 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder IL299381A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US202063071092P 2020-08-27 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (1)

Publication Number Publication Date
IL299381A true IL299381A (en) 2023-02-01

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299381A IL299381A (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Country Status (11)

Country Link
US (1) US20230406928A1 (https=)
EP (1) EP4172211A4 (https=)
JP (1) JP2023534916A (https=)
KR (1) KR20230030642A (https=)
CN (1) CN116234571A (https=)
AU (1) AU2021299307A1 (https=)
BR (1) BR112022026747A2 (https=)
CA (1) CA3178954A1 (https=)
IL (1) IL299381A (https=)
MX (1) MX2022016236A (https=)
WO (1) WO2022006283A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Also Published As

Publication number Publication date
KR20230030642A (ko) 2023-03-06
CA3178954A1 (en) 2022-01-06
US20230406928A1 (en) 2023-12-21
BR112022026747A2 (pt) 2023-01-24
WO2022006283A3 (en) 2022-02-03
WO2022006283A2 (en) 2022-01-06
EP4172211A2 (en) 2023-05-03
JP2023534916A (ja) 2023-08-15
MX2022016236A (es) 2023-03-29
EP4172211A4 (en) 2024-07-10
CN116234571A (zh) 2023-06-06
AU2021299307A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
McGirt et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage
Campolo et al. Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice
Smith et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury
Eibl et al. Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis
IL299381A (en) Methods of treating neuromyelitis optica spectrum disorder
Schwartz et al. Persistent pain is dependent on spinal mitochondrial antioxidant levels
Cavaletti Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we know
Juan et al. Melatonin improves neuroplasticity by upregulating the growth‐associated protein‐43 (GAP‐43) and NMDAR postsynaptic density‐95 (PSD‐95) proteins in cultured neurons exposed to glutamate excitotoxicity and in rats subjected to transient focal cerebral ischemia even during a long‐term recovery period
BR112022008817A2 (pt) Terapias combinadas para tratamento de câncer
BR112022006781A2 (pt) Anticorpos modificados como degradadores moleculares através de receptores celulares
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
Paolin et al. Oxidative damage after severe head injury and its relationship to neurological outcome
Lieder et al. Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes
CY1106879T1 (el) Χρηση των αναστολεων αναγωγασης συνενζυμου α 3-υδροξυ-3-μεθυλογλουταρυλ για την παρασκευη ενος φαρμακου για την αντιμετωπιση της διαβητικης νευροπαθειας
BR112021019520A2 (pt) Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica
Lazarus et al. Protein citrullination: A proposed mechanism for pathology in traumatic brain injury
Nakahashi et al. Role of nerve growth factor-tyrosine kinase receptor A signaling in paclitaxel-induced peripheral neuropathy in rats
Sadowska-Bartosz et al. Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment
Patel et al. High‐dose vitamin B12 in vasodilatory shock: a narrative review
BR112023023558A2 (pt) Anticorpos anti-tmprss6 e usos dos mesmos
WO2024227174A3 (en) Antibodies that bind ox40l and methods of use
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
Lohinai et al. Biofilm lysine decarboxylase, a new therapeutic target for periodontal inflammation
Larsen et al. Serum‐neuroproteins, near‐infrared spectroscopy, and cognitive outcome after beach‐chair shoulder surgery: Observational cohort study analyses
Dietrich et al. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin